Company: Azitra Inc.
Job title: Chief Operating Officer
Outlining ATR-12 for the Treatment of Netherton Syndrome 3:00 pm
Outlining ATR-12 as a novel genetically modified strain of S. epidermidis to be auxotrophic and secrete an active fragment of the full-length LEKTI protein for the treatment of Netherton syndrome (NS) patients, a rare autosomal recessive disease of the skin Revealing studies that show ATR-12 secretes sufficient LEKTI to reverse the underlying causes of NS…Read more
day: Conference Day Two Track B PM 1
Panel Discussion: Getting into the Clinic 12:30 pm
Navigating challenges in entering the clinic Patient stratification, interindividual variation & more Attracting and working with investorsRead more
day: Conference Day Two Track B AM 1